RS61222B1 - Ciklopiroks, ciklopiroksolamin, ili prolek ciklopiroksa za upotrebu u lečenju kancera bešike - Google Patents

Ciklopiroks, ciklopiroksolamin, ili prolek ciklopiroksa za upotrebu u lečenju kancera bešike

Info

Publication number
RS61222B1
RS61222B1 RS20201438A RSP20201438A RS61222B1 RS 61222 B1 RS61222 B1 RS 61222B1 RS 20201438 A RS20201438 A RS 20201438A RS P20201438 A RSP20201438 A RS P20201438A RS 61222 B1 RS61222 B1 RS 61222B1
Authority
RS
Serbia
Prior art keywords
cpx
ciclopirox
pom
bladder cancer
prodrug
Prior art date
Application number
RS20201438A
Other languages
English (en)
Serbian (sr)
Inventor
Scott J Weir
Shrikant Anant
Original Assignee
Univ Kansas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Kansas filed Critical Univ Kansas
Publication of RS61222B1 publication Critical patent/RS61222B1/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
RS20201438A 2014-11-11 2015-11-10 Ciklopiroks, ciklopiroksolamin, ili prolek ciklopiroksa za upotrebu u lečenju kancera bešike RS61222B1 (sr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462078069P 2014-11-11 2014-11-11
US201562134747P 2015-03-18 2015-03-18
EP15859268.3A EP3217980B1 (en) 2014-11-11 2015-11-10 Ciclopirox, ciclopirox olamine, or a ciclopirox prodrug for use in the treatment of bladder cancer
PCT/US2015/059955 WO2016077346A1 (en) 2014-11-11 2015-11-10 Methods of bladder cancer treatment with ciclopirox, ciclopirox olamine, or a ciclopirox prodrug

Publications (1)

Publication Number Publication Date
RS61222B1 true RS61222B1 (sr) 2021-01-29

Family

ID=55954945

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20201438A RS61222B1 (sr) 2014-11-11 2015-11-10 Ciklopiroks, ciklopiroksolamin, ili prolek ciklopiroksa za upotrebu u lečenju kancera bešike

Country Status (12)

Country Link
US (1) US20170304329A1 (enExample)
EP (1) EP3217980B1 (enExample)
JP (1) JP2017533952A (enExample)
CN (2) CN116687941A (enExample)
DK (1) DK3217980T3 (enExample)
ES (1) ES2836208T3 (enExample)
HR (1) HRP20201893T1 (enExample)
HU (1) HUE052670T2 (enExample)
PL (1) PL3217980T3 (enExample)
PT (1) PT3217980T (enExample)
RS (1) RS61222B1 (enExample)
WO (1) WO2016077346A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11753379B2 (en) 2018-05-30 2023-09-12 Clariant International Ltd Process for forming 2-hydroxypyridine-1-oxide or derivatives thereof
CN113194945B (zh) * 2018-08-23 2024-07-23 佩勒梅德有限公司 环吡酮的抑制hbv核心组装的用途
WO2021078937A1 (en) * 2019-10-25 2021-04-29 Deutsches Krebsforschungszentrum Treatment of stat3 related diseases by iron chelators
EP4193989A1 (en) 2021-12-09 2023-06-14 Atlas Molecular Pharma, S.L. A formulation for an effective oral administration of ciclopirox with no adversal gasterointestinal toxicity

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU754965B2 (en) 1997-12-31 2002-11-28 University Of Kansas, The Water soluble prodrugs of tertiary amine containing drugs and methods of making thereof
AU2003251875A1 (en) * 2002-07-15 2004-02-02 Combinatorx, Incorporated Combination therapy for the treatment of neoplasms
WO2010048712A1 (en) 2008-10-31 2010-05-06 University Health Network Ciclopirox and cytarabine for the treatment of leukemic disorders
WO2011153197A1 (en) * 2010-06-01 2011-12-08 Biotheryx, Inc. Hydroxypyridone derivatives, pharmaceutical compositions thereof, and their therapeutic use for treating proliferative diseases
PL2646035T3 (pl) * 2010-12-02 2016-08-31 Univ Kansas Proleki 6-cykloheksylo-1-hydroksy-4-metylopirydyn-2(1h)-onu i ich pochodne

Also Published As

Publication number Publication date
DK3217980T3 (da) 2020-12-07
EP3217980A4 (en) 2018-05-02
HRP20201893T1 (hr) 2021-02-05
ES2836208T3 (es) 2021-06-24
HUE052670T2 (hu) 2021-05-28
US20170304329A1 (en) 2017-10-26
WO2016077346A1 (en) 2016-05-19
CN107206012A (zh) 2017-09-26
JP2017533952A (ja) 2017-11-16
CN116687941A (zh) 2023-09-05
EP3217980B1 (en) 2020-10-14
PL3217980T3 (pl) 2021-03-22
EP3217980A1 (en) 2017-09-20
PT3217980T (pt) 2020-12-11

Similar Documents

Publication Publication Date Title
US10822339B2 (en) Pyrrolopyrimidine five-membered azacyclic derivative and application thereof
US10450305B2 (en) LKB1-AMPK activators for therapeutic use in polycystic kidney disease
US12410156B2 (en) Kinase inhibitors
EP1663219B1 (fr) Derives d'indole pour le traitement de maladies liees au processus d'epissage
EP3113767B1 (en) Mtor-independent activator of tfeb for autophagy enhancement and uses thereof
US9545413B2 (en) Methods of forming ciclopirox or derivatives thereof in a subject by administration of prodrug
JP6568536B2 (ja) パントテン酸キナーゼ関連神経変性症（ｐｋａｎ）の治療のための安定なパンテテイン誘導体およびそのような化合物の合成方法
Prakash et al. Intracellular delivery of the p38 mitogen-activated protein kinase inhibitor SB202190 [4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl) 1 H-imidazole] in renal tubular cells: a novel strategy to treat renal fibrosis
KR101990214B1 (ko) 표적 특이적 항암 약물전구체
EP3217980B1 (en) Ciclopirox, ciclopirox olamine, or a ciclopirox prodrug for use in the treatment of bladder cancer
US9012455B2 (en) Pharmaceutical compositions containing an indoyl isoquinoline containing compound and uses thereof
US20230012172A1 (en) Compositions and methods for treatment of platinum-based chemotherapeutic resistant tumors
Wang et al. A novel and low-toxic peptide DR3penA alleviates pulmonary fibrosis by regulating the MAPK/miR-23b-5p/AQP5 signaling axis
US20160221907A1 (en) MTOR-independent activator of TFEB for autophagy enhancement and uses thereof
US10494365B2 (en) Small molecule inhibitor of 3-phosphoglycerate dehydrogenase and uses thereof
Wang et al. Discovery of a novel EGFR PROTAC degrader against C797S resistance mutation with potent antitumor efficacy in NSCLC treatment
US20190382330A1 (en) Novel ester compound and pin1 inhibitor, inflammatory disease therapeutic, and colon cancer therapeutic in which said ester compound is used
US9399644B2 (en) [1,3] dioxolo [4,5-G] quinoline-6(5H)thione derivatives as inhibitors of the late SV40 factor (LSF) for use in treating cancer
US20230322853A1 (en) Compounds and compositions for the treatment of proliferative diseases and disorders
CN102532192B (zh) 一种对乙酰氨基酚—磷酰氮芥抗肿瘤药物及其制备方法
Prakash et al. Intracellular delivery of the P38 MAPK inhibitor SB202190 in renal tubular cells: a novel strategy to treat renal fibrosis
EP3558304A2 (en) Inhibitors of cytochrome p450 family 7 subfamily b member 1 (cyp7b1) for use in treating diseases
WO2025194120A1 (en) Zwitterionic polymer functionalized lipid nanoparticles for delivery of nucleic acids
US20090131511A1 (en) Palmarumycin based inhibitors of thioredoxin and methods of using same
Prakash Renal-specific delivery of antifibrotic drugs using lysozyme: a novel approach for the treatment of renal fibrosis